About Vybion
Vybion has pioneered vectorized Intrabodies, the delivery of functional antibody fragments in the scFv format to cells using Adeno associated virus (AAV). The Company has Orphan Drug Designation from the FDA for INT41 to treat Huntington’s disease a progressively fatal protein aggregating condition leading to loss of neurons. A recent preIND meeting has established IND enabling work to be completed before submitting and IND to start human clinical trials.
Lee has developed IND enabling processes for 12 biologic drugs in multiple therapeutic areas and actively manages licensing, M&A and IP for over 24 years. Lee spent 15 years in academics before starting Viral Therapeutics which was sold to Meridian Biosciences. He helped fund and launch GeneWeave Biosciences through Series A which was sold to Roche.
Martin has held positions as a Director of Teva Pharmaceuticals managing Venture Capital investments. Director or Senior Manager positions at Amgen, Eli Lilly and Genetic Therapy. Scientific background in Gene Therapy, Neurodegenerative diseases and corporate background in Licensing, Strategic Planning, Partner Agreement Negotiation, M&A and International Relationship Building.
Regulatory professional with over 20 years of pharmaceutical industry experience (Genentech, Gilead, Adamas, CDC). Â Experienced with expedited review designations (breakthrough therapy, fast track), special populations, rare disease, and orphan drug indications, and INDs, NDAs, BLAs, MAAs. CTAs.
Rick has filled various financial management roles at US Steel, Baker Hughes, MMI Products and Hardinge, Inc. in addition to serving as a transitional CFO for a number of startup companies. His experience includes, financial forecasting, due diligence, M&A, private financings, risk management, SEC reporting and with a broad range of management and reporting responsibilities.